Arcutis Biotherapeutics Appoints Amit Munshi as New Director
TipRanks (Mon, 8-Dec 4:44 PM ET)
Globe Newswire (Mon, 8-Dec 4:00 PM ET)
Globe Newswire (Mon, 17-Nov 8:00 AM ET)
Globe Newswire (Thu, 13-Nov 8:00 AM ET)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 7-Nov 4:00 PM ET)
Globe Newswire (Tue, 4-Nov 8:00 AM ET)
Globe Newswire (Thu, 30-Oct 9:15 AM ET)
Globe Newswire (Thu, 30-Oct 8:00 AM ET)
Arcutis Highlights Robust Dermatology Pipeline Ahead of Major Investor Conferences
Market Chameleon (Tue, 28-Oct 6:29 AM ET)
Market Chameleon (Tue, 28-Oct 5:06 AM ET)
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Arcutis Biotherapeutics trades on the NASDAQ stock market under the symbol ARQT.
As of December 9, 2025, ARQT stock price declined to $30.08 with 348,505 million shares trading.
ARQT has a beta of 0.26, meaning it tends to be less sensitive to market movements. ARQT has a correlation of 0.01 to the broad based SPY ETF.
ARQT has a market cap of $3.68 billion. This is considered a Mid Cap stock.
Last quarter Arcutis Biotherapeutics reported $99 million in Revenue and $.06 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.16.
In the last 3 years, ARQT traded as high as $31.77 and as low as $1.76.
The top ETF exchange traded funds that ARQT belongs to (by Net Assets): VTI, IWM, XBI, IWO, VXF.
ARQT has outperformed the market in the last year with a return of +142.6%, while the SPY ETF gained +13.7%. In the last 3 month period, ARQT beat the market returning +73.6%, while SPY returned +5.7%. However, in the most recent 2 weeks ARQT has underperformed the stock market by returning -2.2%, while SPY returned +2.3%.
ARQT support price is $29.78 and resistance is $32.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARQT shares will trade within this expected range on the day.
